Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Follow-Up Questions
ABPRO Holdings Inc의 CEO는 누구입니까?
Mr. Jin Wook Suk은 2024부터 회사에 합류한 ABPRO Holdings Inc의 Chairman of the Board입니다.
ABP 주식의 가격 성능은 어떻습니까?
ABP의 현재 가격은 $5.88이며, 전 거래일에 increased 11.58% 하였습니다.
ABPRO Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
ABPRO Holdings Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
ABPRO Holdings Inc의 시가총액은 얼마입니까?
ABPRO Holdings Inc의 현재 시가총액은 $471.4M입니다
ABPRO Holdings Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 2명의 분석가가 ABPRO Holdings Inc에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
